Clarity Pharmaceuticals has secured a significant commercial manufacturing partnership with SpectronRx that could transform access to next-generation prostate cancer diagnostics in the United States. The five-year agreement, effective June 17, 2025, positions the clinical-stage radiopharmaceutical company to produce up to 400,000 patient-ready doses of Cu-SAR-bisPSMA annually from SpectronRx's Indiana facility.
Addressing Critical Supply Chain Limitations
The partnership directly tackles longstanding logistical challenges in the radiopharmaceutical field. Current-generation PSMA diagnostics rely on isotopes with significantly shorter half-lives - gallium-68 and fluorine-18 have half-lives of approximately one hour and two hours, respectively, compared to copper-64's optimal 12.7-hour half-life.
"These short half-lives translate into short shelf-lives, constraining availability of these agents to a restricted number of locations at specific times, which often do not align to the clinical needs of the sites or the patients' needs," explained Dr. Alan Taylor, Clarity's Executive Chairperson.
The gallium-68 supply chain requires substantial ongoing capital investment to maintain a network of generators that last only six months each. Most generators are manufactured outside the US, creating potential exposure to tariffs. Meanwhile, fluorine-18 for PSMA applications competes directly with the established 18F-FDG market for isotope sourcing, significantly impacting supply availability.
Integrated Manufacturing Approach
SpectronRx's facility will provide on-demand commercial-scale manufacturing of both copper-64 and Cu-SAR-bisPSMA under one roof, enabling distribution to all 50 states. The copper-64 production and purification process, developed over 30 years ago, offers a proven, streamlined approach that SpectronRx has scaled for large commercial markets.
"Broad, on-demand distribution, enabled by a shelf-life of up to 48 hours, combined with ease of central manufacture and the ability to produce up to 400,000 patient-ready Cu-SAR-bisPSMA doses annually under one roof from SpectronRx's facility in Indiana, is a game-changer for the radiopharmaceutical field," Taylor stated.
John Zehner, CEO of SpectronRx, emphasized the collaboration's potential impact: "Partnering with Clarity marks a significant step forward in expanding access to radiopharmaceuticals and improving healthcare outcomes in the United States."
Scalable Production Strategy
The agreement includes options to expand integrated Cu-SAR-bisPSMA manufacturing to additional US locations, substantially increasing overall production capacity through regional hubs. This multi-layered supply approach is described as unique in the radiopharmaceutical space, allowing for national, regional, and local production strategies.
SpectronRx is already producing small quantities of Cu-SAR-bisPSMA for Clarity's Phase III registrational trials, CLARIFY and AMPLIFY, which are required for FDA New Drug Application approval. The company operates over 200,000 square feet of production space in Indiana, with additional facilities in Connecticut and Europe, and currently supplies radiopharmaceuticals to 29 countries.
Technology Platform Advantages
Cu-SAR-bisPSMA utilizes Clarity's proprietary sarcophagine (SAR) technology, which securely holds copper isotopes inside a cage-like chelator structure. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. The compound derives its name from "bis," reflecting a novel approach of connecting two PSMA-targeting agents to the SAR platform.
The Targeted Copper Theranostic can be used with copper-64 for imaging and copper-67 for therapy, positioning it as a comprehensive diagnostic and treatment platform for prostate cancer patients.
Commercial Readiness
The manufacturing agreement supplements Clarity's existing supply and manufacturing agreements, creating what the company describes as a multi-layered and abundant approach to production. Taylor noted that this comprehensive supply chain preparation ensures readiness for immediate commercial rollout upon FDA approval.
"This Agreement, combined with other supply and manufacturing agreements for isotope and finished product we have secured to date, ensures that we are ready to roll out large-scale manufacturing and distribution of Cu-SAR-bisPSMA on day one of commercialisation," Taylor said.
The partnership aims to enable seamless access to the diagnostic at any US treatment facility with a positron emission tomography (PET) scanner, 24 hours a day, seven days a week, addressing current accessibility limitations in prostate cancer diagnostics.
